Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Next Generation Sequencing (NGS) is the fastest growing segment, North America is the largest regional market

The Global Liquid Biopsy Market, valued at USD 4.93 Billion in 2024, is projected to experience a CAGR of 12.50% to reach USD 9.99 Billion by 2030. The global liquid biopsy market focuses on diagnostic tests that detect and analyze genetic material, such as circulating tumor DNA and circulating tumor cells, present in bodily fluids, primarily blood. This non-invasive approach facilitates early cancer detection, treatment monitoring, and identification of genetic mutations, offering advantages over traditional tissue

Key Market Drivers

The global liquid biopsy market's expansion is fundamentally propelled by the escalating worldwide cancer burden. The significant increase in cancer diagnoses necessitates accessible, less invasive diagnostic and monitoring tools. According to the World Health Organization and the International Agency for Research in Cancer, in their February 2024 news release "Global cancer burden growing, amidst mounting need for services", an estimated 20 million new cancer cases occurred worldwide in 2022. This prevalence drives demand for technologies enabling early detection, treatment guidance, and disease monitoring with minimal patient discomfort. Increasing regulatory and clinical validation supports market penetration.

Key Market Challenges

The prevailing concern regarding test accuracy and the absence of universally standardized procedures across various platforms presents a significant impediment to the growth of the global liquid biopsy market. The lack of consistent protocols for assay development, validation, and reporting contributes to variable test performance and potentially inaccurate outcomes. This directly undermines the confidence of healthcare providers in integrating liquid biopsy into routine clinical practice, slowing its broader adoption.

For example, according to a 2024 International Association for the Study of Lung Cancer Global Survey, 26% of surveyed institutions were unaware of any biomarker testing guidelines, while only 54% utilized the comprehensive CAP-IASLC-AMP guidelines. Such discrepancies in guideline awareness and implementation highlight the fragmented landscape of liquid biopsy utilization. This variability complicates comparative analysis across different platforms and laboratories, making it difficult for clinicians to fully trust and rely on the results for critical treatment decisions. Consequently, the market experiences slower expansion as stakeholders exercise caution due to these unresolved issues in standardization and perceived reliability.

Key Market Trends

Multi-analyte and multi-cancer screening development is significantly driving the global liquid biopsy market by enabling the simultaneous detection of various cancer types from a single blood sample. This trend promotes broader, earlier cancer identification, enhancing preventative care and treatment outcomes. In March 2024, the National Institutes of Health launched its Cancer Screening Research Network to evaluate multi-cancer early detection tests, initiating a Vanguard Study enrolling up to 24,000 participants. This highlights national commitment to validating advanced diagnostics. Further demonstrating progress, Exai Bio presented data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, showing its RNA- and AI-based platform achieved 87% overall stage I sensitivity across eight cancer types at 95% specificity in a 3,300 subject study.

Key Market Players Profiled:

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
LungLife AI, Inc.
Illumina, Inc.
QIAGEN NV
NeoGenomics Laboratories, Inc.
Myriad Genetics, Inc.
Bio-Rad Laboratories, Inc.
Guardant Health Inc.
Natera, Inc.
Sysmex Corporation
Abcodia Ltd.
Dxcover Limited

Report Scope:

In this report, the Global Liquid Biopsy Market has been segmented into the following categories:

By Offering:

Testing Services
Kits
Platform
Other Consumables

By Technology:

Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Others

By Workflow:

Sample Preparation
Library Preparation
Sequencing
Data Analysis & Management

By Sample:

Blood
Urine
Saliva
Others

By Circulating Biomarkers:

Circulating Tumor Cells (CTCs)
Cell-free Nucleic Acids
Exosomes & Extracellular Vesicles

By Application:

Oncological
Non-oncological

By End User:

Clinical Laboratories
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies

By Region:

North America
Europe
Asia-Pacific
South America
Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liquid Biopsy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liquid Biopsy Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Offering (Testing Services, Kits, Platform, Other Consumables)
5.2.2. By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others)
5.2.3. By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management)
5.2.4. By Sample (Blood, Urine, Saliva, Others)
5.2.5. By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles)
5.2.6. By Application (Oncological, Non-oncological)
5.2.7. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)
5.2.8. By Region
5.2.9. By Company (2024)
5.3. Market Map

6. North America Liquid Biopsy Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Offering
6.2.2. By Technology
6.2.3. By Workflow
6.2.4. By Sample
6.2.5. By Circulating Biomarkers
6.2.6. By Application
6.2.7. By End User
6.2.8. By Country
6.3. North America: Country Analysis
6.3.1. United States Liquid Biopsy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Offering
6.3.1.2.2. By Technology
6.3.1.2.3. By Workflow
6.3.1.2.4. By Sample
6.3.1.2.5. By Circulating Biomarkers
6.3.1.2.6. By Application
6.3.1.2.7. By End User
6.3.2. Canada Liquid Biopsy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Offering
6.3.2.2.2. By Technology
6.3.2.2.3. By Workflow
6.3.2.2.4. By Sample
6.3.2.2.5. By Circulating Biomarkers
6.3.2.2.6. By Application
6.3.2.2.7. By End User
6.3.3. Mexico Liquid Biopsy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Offering
6.3.3.2.2. By Technology
6.3.3.2.3. By Workflow
6.3.3.2.4. By Sample
6.3.3.2.5. By Circulating Biomarkers
6.3.3.2.6. By Application
6.3.3.2.7. By End User

7. Europe Liquid Biopsy Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Offering
7.2.2. By Technology
7.2.3. By Workflow
7.2.4. By Sample
7.2.5. By Circulating Biomarkers
7.2.6. By Application
7.2.7. By End User
7.2.8. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Liquid Biopsy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Offering
7.3.1.2.2. By Technology
7.3.1.2.3. By Workflow
7.3.1.2.4. By Sample
7.3.1.2.5. By Circulating Biomarkers
7.3.1.2.6. By Application
7.3.1.2.7. By End User
7.3.2. France Liquid Biopsy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Offering
7.3.2.2.2. By Technology
7.3.2.2.3. By Workflow
7.3.2.2.4. By Sample
7.3.2.2.5. By Circulating Biomarkers
7.3.2.2.6. By Application
7.3.2.2.7. By End User
7.3.3. United Kingdom Liquid Biopsy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Offering
7.3.3.2.2. By Technology
7.3.3.2.3. By Workflow
7.3.3.2.4. By Sample
7.3.3.2.5. By Circulating Biomarkers
7.3.3.2.6. By Application
7.3.3.2.7. By End User
7.3.4. Italy Liquid Biopsy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Offering
7.3.4.2.2. By Technology
7.3.4.2.3. By Workflow
7.3.4.2.4. By Sample
7.3.4.2.5. By Circulating Biomarkers
7.3.4.2.6. By Application
7.3.4.2.7. By End User
7.3.5. Spain Liquid Biopsy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Offering
7.3.5.2.2. By Technology
7.3.5.2.3. By Workflow
7.3.5.2.4. By Sample
7.3.5.2.5. By Circulating Biomarkers
7.3.5.2.6. By Application
7.3.5.2.7. By End User

8. Asia-Pacific Liquid Biopsy Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Offering
8.2.2. By Technology
8.2.3. By Workflow
8.2.4. By Sample
8.2.5. By Circulating Biomarkers
8.2.6. By Application
8.2.7. By End User
8.2.8. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Liquid Biopsy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Offering
8.3.1.2.2. By Technology
8.3.1.2.3. By Workflow
8.3.1.2.4. By Sample
8.3.1.2.5. By Circulating Biomarkers
8.3.1.2.6. By Application
8.3.1.2.7. By End User
8.3.2. India Liquid Biopsy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Offering
8.3.2.2.2. By Technology
8.3.2.2.3. By Workflow
8.3.2.2.4. By Sample
8.3.2.2.5. By Circulating Biomarkers
8.3.2.2.6. By Application
8.3.2.2.7. By End User
8.3.3. Japan Liquid Biopsy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Offering
8.3.3.2.2. By Technology
8.3.3.2.3. By Workflow
8.3.3.2.4. By Sample
8.3.3.2.5. By Circulating Biomarkers
8.3.3.2.6. By Application
8.3.3.2.7. By End User
8.3.4. South Korea Liquid Biopsy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Offering
8.3.4.2.2. By Technology
8.3.4.2.3. By Workflow
8.3.4.2.4. By Sample
8.3.4.2.5. By Circulating Biomarkers
8.3.4.2.6. By Application
8.3.4.2.7. By End User
8.3.5. Australia Liquid Biopsy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Offering
8.3.5.2.2. By Technology
8.3.5.2.3. By Workflow
8.3.5.2.4. By Sample
8.3.5.2.5. By Circulating Biomarkers
8.3.5.2.6. By Application
8.3.5.2.7. By End User

9. Middle East & Africa Liquid Biopsy Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Offering
9.2.2. By Technology
9.2.3. By Workflow
9.2.4. By Sample
9.2.5. By Circulating Biomarkers
9.2.6. By Application
9.2.7. By End User
9.2.8. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Liquid Biopsy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Offering
9.3.1.2.2. By Technology
9.3.1.2.3. By Workflow
9.3.1.2.4. By Sample
9.3.1.2.5. By Circulating Biomarkers
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. UAE Liquid Biopsy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Offering
9.3.2.2.2. By Technology
9.3.2.2.3. By Workflow
9.3.2.2.4. By Sample
9.3.2.2.5. By Circulating Biomarkers
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. South Africa Liquid Biopsy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Offering
9.3.3.2.2. By Technology
9.3.3.2.3. By Workflow
9.3.3.2.4. By Sample
9.3.3.2.5. By Circulating Biomarkers
9.3.3.2.6. By Application
9.3.3.2.7. By End User

10. South America Liquid Biopsy Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Offering
10.2.2. By Technology
10.2.3. By Workflow
10.2.4. By Sample
10.2.5. By Circulating Biomarkers
10.2.6. By Application
10.2.7. By End User
10.2.8. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Liquid Biopsy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Offering
10.3.1.2.2. By Technology
10.3.1.2.3. By Workflow
10.3.1.2.4. By Sample
10.3.1.2.5. By Circulating Biomarkers
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. Colombia Liquid Biopsy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Offering
10.3.2.2.2. By Technology
10.3.2.2.3. By Workflow
10.3.2.2.4. By Sample
10.3.2.2.5. By Circulating Biomarkers
10.3.2.2.6. By Application
10.3.2.2.7. By End User
10.3.3. Argentina Liquid Biopsy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Offering
10.3.3.2.2. By Technology
10.3.3.2.3. By Workflow
10.3.3.2.4. By Sample
10.3.3.2.5. By Circulating Biomarkers
10.3.3.2.6. By Application
10.3.3.2.7. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Liquid Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific, Inc.
15.3. PerkinElmer Inc.
15.4. LungLife AI, Inc.
15.5. Illumina, Inc.
15.6. QIAGEN NV
15.7. NeoGenomics Laboratories, Inc.
15.8. Myriad Genetics, Inc.
15.9. Bio-Rad Laboratories, Inc.
15.10. Guardant Health Inc.
15.11. Natera, Inc.
15.12. Sysmex Corporation
15.13. Abcodia Ltd.
15.14. Dxcover Limited

16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

The companies profiled in this Liquid Biopsy market report include:

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
LungLife AI, Inc.
Illumina, Inc.
QIAGEN NV
NeoGenomics Laboratories, Inc.
Myriad Genetics, Inc.
Bio-Rad Laboratories, Inc.
Guardant Health Inc.
Natera, Inc.
Sysmex Corporation
Abcodia Ltd.
Dxcover Limited

Table Information

Report Attribute	Details
No. of Pages	185
Published	November 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 4.93 Billion
Forecasted Market Value ( USD ) by 2030	$ 9.99 Billion
Compound Annual Growth Rate	12.5%
Regions Covered	Global
No. of Companies Mentioned	15

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4019EUR$4,500USD£3,517GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4912EUR$5,500USD£4,299GBP